Capital Research Global Investors
BIO icon

Capital Research Global Investors’s Bio-Rad Laboratories Class A BIO Stock Holding History

Capital Research Global Investors’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$107M Sell
385,579
-108,893
-22% -$31.4M 0.02% 302
2025
Q4 		$150M Buy
494,472
+76,117
+18% +$23.8M 0.03% 263
2025
Q3 		$117M Buy
+418,355
New +$114M 0.02% 284

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $59.9B AUM 27.01% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Capital Research Global Investors's BIO Position: Q1 2026 in Review

Capital Research Global Investors reduced its Bio-Rad Laboratories Class A (BIO) stake by 22% in Q1 2026, selling an estimated $31.4M and leaving 385,579 shares worth $107M. The position accounts for 0.02% of the portfolio, ranked #302.

Capital Research Global Investors first reported a position in BIO in Q3 2025 and has held it in 3 quarters since. The position peaked at $150M in Q4 2025. 393 funds tracked by Wall St. Rank hold BIO as of Q1 2026.

  • Capital Research Global Investors held 385,579 shares of Bio-Rad Laboratories Class A worth $107M as of Q1 2026.
  • Capital Research Global Investors sold 108,893 Bio-Rad Laboratories Class A shares in Q1 2026, an estimated $31.4M.
  • Bio-Rad Laboratories Class A made up 0.02% of Capital Research Global Investors's portfolio in Q1 2026, its #302 holding.
  • Capital Research Global Investors first reported a position in Bio-Rad Laboratories Class A in Q3 2025 and has held it in 3 quarters since.
  • Capital Research Global Investors's Bio-Rad Laboratories Class A position peaked at $150M in Q4 2025.
  • 393 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q1 2026.

Based on Capital Research Global Investors's 13F filing for Q1 2026, filed 13 May 2026.